Skip to contentC
China Pharma Holdings, Inc.
C
CPHIChina Pharma Holdings, Inc. Q3 2021 · 10-Q
Revenue$1.98M$1.98M−17.6% vs Q3 2020 Net Income-$826.67K-$826.67KN/M vs Q3 2020 EPS Diluted-$0.02-$0.02N/M vs Q3 2020 The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
China Pharma Holdings, Inc. · CIK 1106644 · Engraved from SEC EDGAR
Operating Cash Flowderived-$450,846N/M Free Cash Flowderived-$866,823N/M Margins · derivedGross margin-15.0%−16.9 pt vs Q3 2020
Operating margin-38.5%+1.1 pt vs Q3 2020
Net margin-41.8%+0.3 pt vs Q3 2020
ended Sep 30, 2021 · filed Nov 12, 2021 · 43 d after period end